Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Late Breaking Clinical Trials 2: Late Breaking Science in Prevention

• REAL-CAD
  RESULTS: Higher intensity pitavastatin therapy lowered LDL-C and reduced adverse cardiovascular events more than moderate-intensity pitavastatin therapy in this Japanese study population.
• REVEAL
  RESULTS: Major coronary events lower with anacetrapib for patients with and without DM.
• FOURIER
  RESULTS: In patients with PAD, evolocumab significantly reduced LDL-C and major cardiovascular events, including death, heart attack, and stroke.
• FOURIER with MI – Analysis
  RESULTS: In patients with a prior MI, evolocumab significantly reduced the risk for major cardiovascular events, including death, heart attack, and stroke.
• CANTOS 
  RESULTS: Targeting inflammatory pathways with canakinumab reduced rates of adverse cardiovascular events.

Late Breaking Clinical Trials 3: Latest Insights into Hypertension Management

• BP TITRE
  RESULTS: More time spent at the target blood pressure resulted in a lower risk for cardiovascular disease and death.
• SPRINT
  RESULTS: Blood pressure control was similar even with different levels of BP attendance.
• GATEWAY
  RESULTS: Bariatric surgery reduced the need for antihypertensive drugs while keeping blood pressure controlled.

Late Breaking Clinical Trials 4: Sweet Spot in Cardiometabolic Care

• CANVAS 
  RESULTS: Canagliflozin reduced adverse cardiovascular events for patient with type 2 diabetes and no history of cardiovascular disease.
• EXSCEL 
  RESULTS: The treatment effect of exenatide was similar across all risk groups (low – high) for clinical outcomes, regardless of baseline risk. Baseline risk did not predict clinical benefit.
• EMPA-REG OUTCOME
  RESULTS: In these patients with HF, T2DM, and PAD, empagliflozin compared to placebo reduced the risk of cardiovascular and all-cause death, and HF hospitalizations.
• BiomarCaRE 
  RESULTS: In the general population, 4 metabolites were noted to be inversely associated with coronary heart disease. This may aid risk stratification.

Other studies of note published Monday

• Circulation: Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study
  Jacob A. Udell | University of Toronto, Toronto, ON, Canada